Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

European Journal of Cancer

Volumn 37, Issue 8, 2001, Pages 972-978

  Kosmas, C ^a   Tsavaris, N ^b   Panopoulos, C ^c   Vadiaka, M ^b   Stavroyianni, N ^b   Kourelis, Th ^d   Malamos, N ^a   Antonopoulos, M ^a   Kalofonos, H P ^d  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Gemcitabine; Ifosfamide; Non small cell lung cancer; Paclitaxel; Vinorelbine

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PATIENT COMPLIANCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0035031894     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00419-6     Document Type: Article

References (32)

1. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
2. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vindesine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
3. Gemcitabine: Single agent and combination therapy in non-small cell lung cancer
4. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
5. Phase II study of docetaxel (Taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer
6. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
7. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer
8. Salvage therapy with gemcitabine in advanced non-small cell lung cancer progressing after prior carboplatin-paclitaxel
9. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial
10. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
11. A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer
12. Phase I study of dose escalated paclitaxel, ifosfamide, and cisplatin combination chemotherapy in advanced solid tumours
13. Non-parametric estimation from incomplete observations
14. Confidence interval for reporting results of clinical trials
15. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent
16. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group
17. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network phase II trial
18. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer
19. Activity of gemcitabine in cisplatin-pretreated patients with advanced non-small cell lung cancer: A phase II trial
20. Gemcitabine in platinum treated non-small cell lung cancer
21. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
22. Failure of vinorelbine to produce responses in pretreated non-small-cell lung cancer
23. Vinorelbine as single agent in the treatment of advanced non-small-cell lung cancer
24. Phase III study of gemcitabine versus best supportive care in advanced non-small cell lung cancer
25. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer
26. Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): A phase I trial
27. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients 70 years or older or patients who cannot receive cisplatin
28. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB and IV non-small-cell lung cancer
29. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: A phase II study
30. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
31. Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study
32. Gemcitabine+vinorelbine yields better survival than vinorelbine alone in elderly non-small cell lung cancer patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial